Investigating the long-term legacy of statin therapy
- PMID: 28523141
- PMCID: PMC5418248
- DOI: 10.21037/jtd.2017.03.10
Investigating the long-term legacy of statin therapy
Conflict of interest statement
Conflicts of Interest: SJ Nicholls reports having received research support from Anthera, AstraZeneca, Amgen, Cerenis, Eli Lilly, Novartis, Resverlogix and Sanofi-Regeneron and is a consultant for AstraZeneca, Amgen, Boehringer Ingelehim, CSL Behring, Cerenis, Eli Lilly, Kowa, Merck, Novartis, Pfizer, Resverlogix, Roche, Sanofi-Regeneron and Takeda. The other authors have no conflicts of interest to declare.
Comment on
-
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.Circulation. 2016 Mar 15;133(11):1073-80. doi: 10.1161/CIRCULATIONAHA.115.019014. Epub 2016 Feb 10. Circulation. 2016. PMID: 26864092 Free PMC article.
References
-
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources